Talk:Sorafenib
| This is the talk page for discussing improvements to the Sorafenib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Sorafenib.
|
Cipla a leading pharmaceutical company of India is planning to launch this molecule in india market in generic form. According to company information, The cost of treatment for Kidney cancer from branded medicine
Common skin side effects
editHCC Patient on Sorafenib Develops Two Nodules says
- "Cutaneous toxicity, however, is relatively common, perhaps even approaching 90%, in patients receiving this medication. The most frequent skin side effects include: a nonspecific maculopapular rash (34%), hand-foot syndrome (27% to 60%), initial appearance or worsening of psoriasis, facial erythema with or without edema, erythema multiforme, subungual splinter hemorrhages, stomatitis, alopecia, xerosis, eruptive nevi, inflammation of existent seborrheic keratoses, and induction of premalignant and malignant skin tumors.[4,5] Since the first report of sorafenib-associated squamous cell carcinoma in 2006,[6] about 50 patients have been reported to demonstrate cutaneous lesions with epithelial (epidermal) atypia, including an unmasking of numerous actinic keratoses, appearance of the classic keratoacanthoma subtype of squamous cell carcinoma, and development of classic ulcerated nodules of invasive squamous cell carcinoma." and
- "it is noteworthy that other multikinase inhibitor agents that share a similar mechanism of action do not share this relatively high predisposition toward inducing cutaneous neoplasms." - Rod57 (talk) 23:57, 10 October 2011 (UTC)
External links modified
editI have just added archive links to one external link on Sorafenib. Please take a moment to review my edit. ... I made the following changes:
- Added archive https://web.archive.org/20131203054054/http://www.lifescience-online.com/,18181?portalPage=Lifescience+Today.News to http://www.lifescience-online.com/,18181?portalPage=Lifescience+Today.News
- cyberbot II 06:26, 15 February 2016 (UTC)
- Deleted as the (poor) ref is no longer used/needed by the article - Rod57 (talk) 14:27, 7 July 2017 (UTC)
Adverse effects section seems excessive
editMost of the footnotes add nothing - none of the side effects have a source, and which of the rare side effects are notable ? - how do they compare with the control groups ? Could delete the footnotes and the lower half of the section, and mark as needing RS ? - Rod57 (talk) 14:25, 7 July 2017 (UTC)
- Agree. Both the uncurated list of side effects and footnoting are inappropriate. Dr G (talk) 18:27, 29 December 2017 (UTC)
Structure in the box is incorrect
editThe 2D structure in the box is incorrect, while the 3D structure is fine. The pyridine nitrogen should be moved to the position oposite to the phenolic oxygen. 147.231.120.62 (talk) 14:56, 27 October 2023 (UTC)